Post-Marketing Surveillance of Acarbose Treatment in Patients with Type 2 Diabetes Mellitus and Subjects with Impaired Glucose Tolerance in China

Pan, Changyu; Landen, H.

doi:10.2165/00044011-200727060-00003

Cited by 22 publications

(20 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…22 Our data contradict this finding. Prior to severity adjustment, a detrimental effect was associated with acarbose (OR = 2.141, 95% CI from 1.335 to 3.435).…”

Section: Relationship Between Composite Severity and Mortalitycontrasting

confidence: 82%

Comparative Effectiveness of Hypoglycemic Medications Among Veterans

Kheirbek

Alemi²,

Zargoush³

2013

JMCP

View full text Add to dashboard Cite

show abstract

“…22 Our data contradict this finding. Prior to severity adjustment, a detrimental effect was associated with acarbose (OR = 2.141, 95% CI from 1.335 to 3.435).…”

Section: Relationship Between Composite Severity and Mortalitycontrasting

confidence: 82%

Comparative Effectiveness of Hypoglycemic Medications Among Veterans

Kheirbek

Alemi²,

Zargoush³

2013

JMCP

View full text Add to dashboard Cite

show abstract

“…In a German surveillance study with a fixed increasing dosage regimen in 27,803 patients, the incidence was 13%,64 and the incidence was 3.9% in 1996 German patients with free dosing of acarbose in a 5-year post-marketing surveillance study 59. Post-marketing surveillance studies in China and other Asian countries showed an incidence of 2% in 14,418 patients,51 and of only 0.6% in a Chinese post-marketing surveillance study in 2550 patients 65. There are several reasons for these differences in rates.…”

Section: Significance Of Acarbose Properties For the Patientmentioning

confidence: 91%

Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations

Rosak¹,

Mertes²

2012

DMSO

180

112

View full text Add to dashboard Cite

The alpha-glucosidase inhibitor acarbose has been used for more than 20 years in the management of hyperglycemia. Owing to its unique mode of action in the gastrointestinal tract, its properties are very different from other antidiabetic medications. Patients on long-term treatment to control a chronic disease are not only interested in good treatment efficacy, but are also even more interested in the safety and side effects of their medications. Significant aspects of acarbose predominantly regarding safety and tolerability in the management of type 2 diabetes and prediabetes are reviewed. It is concluded that acarbose is a convenient long-term treatment option, with benefits for both type 2 diabetics and patients in a prediabetic state.

show abstract

“…Studies assessing the efficacy and safety of acarbose performed in both mainland China and Taiwan reported that acarbose reduced HbA 1c levels by 1% to 1.5% 20,21. Similar studies performed in the USA, Germany, and Italy reported reductions of 0.7%, 1.8%, and 0.14%, respectively 34–36.…”

Section: Therapeutic Efficacymentioning

confidence: 76%

“…The efficacy of acarbose in Chinese patients with T2DM has been confirmed in a number of controlled trials 20–26. Most of these studies were designed to assess the potential non-inferiority of acarbose compared with other therapeutic agents.…”

Section: Therapeutic Efficacymentioning

confidence: 97%

Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients

He¹,

Shi²,

Mao³

2014

TCRM

View full text Add to dashboard Cite

Acarbose is an α-glucosidase inhibitor that is commonly used to control postprandial blood glucose. It functions as a competitive and reversible inhibitor of small intestinal brush border glucosidase, blocks the degradation of starch and sucrose, and delays the absorption of glucose and fructose in the alimentary tract. The starch content of a diet might alter the hypoglycemic effects of acarbose because of its mechanism of action. Chinese individuals consume a typical Eastern diet, which is characterized by a high intake of whole grains, legumes, vegetables, fruits, and fish. These dietary habits allow acarbose to be used extensively in the People’s Republic of China. Several Chinese-based studies have demonstrated that the use of acarbose as a monotherapy had similar effects on other anti-diabetes agents in decreasing glycosylated hemoglobin (HbA1c) and blood glucose levels, and acarbose in combination with other anti-diabetic drugs could further reduce blood glucose and decrease the mean amplitude of glycemic excursions. Importantly, acarbose is safe and well tolerated, with a low incidence of adverse effects. This article provides a comprehensive review of the safety and efficacy of acarbose for the treatment of diabetes in Chinese patients.

show abstract

Post-Marketing Surveillance of Acarbose Treatment in Patients with Type 2 Diabetes Mellitus and Subjects with Impaired Glucose Tolerance in China

Abstract: Acarbose was efficacious, safe and well accepted by Chinese patients with type 2 diabetes and subjects with IGT under day-to-day treatment conditions, both as monotherapy and in combination with other antihyperglycaemic medication.

Cited by 22 publications

References 35 publications

Comparative Effectiveness of Hypoglycemic Medications Among Veterans

Comparative Effectiveness of Hypoglycemic Medications Among Veterans

Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations

Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients

Contact Info

Product

Resources

About